Carfilzomib · 2026 May 12
Belantamab mafodotin, carfilzomib, lenalidomide, and dexamethasone for relapsed or refractory multiple myeloma.
Journal Article, Clinical Trial, Phase II, Clinical Trial, Phase I
Open attributed record →PubMed-attributed venue
6 selected PubMed bibliographic records attributed to Blood advances. Venue attribution is reproduced from PubMed and does not imply endorsement, editorial affiliation, article quality, or scientific validity.
6 selected records.
3 connected profiles.
5 attributed years.
Attributed bibliography
Carfilzomib · 2026 May 12
Journal Article, Clinical Trial, Phase II, Clinical Trial, Phase I
Open attributed record →Carfilzomib · 2025 Feb 11
Journal Article, Clinical Trial, Phase II
Open attributed record →Pegcetacoplan · 2024 Jun 11
Journal Article, Clinical Trial, Phase III, Randomized Controlled Trial, Multicenter Study, Research Support, Non-U.S. Gov't
Open attributed record →Carfilzomib · 2023 Oct 10
Clinical Trial, Phase II, Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't
Open attributed record →Carfilzomib · 2023 Apr 11
Clinical Trial, Phase I, Journal Article
Open attributed record →Desmopressin · 2022 Jun 28
Journal Article, Meta-Analysis, Systematic Review, Research Support, Non-U.S. Gov't
Open attributed record →